Business Context and Reporting Period
This Form 8-K was filed by ADVENTRX Pharmaceuticals, Inc. on January 2, 2013. The report discloses a change in senior management and associated compensatory arrangements. Note: The request metadata references "Savara Inc," but the filing text explicitly identifies the registrant as ADVENTRX Pharmaceuticals, Inc.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and personnel changes.
Material Changes
- Executive Appointment: Brandi L. Roberts was promoted to Chief Financial Officer (CFO) and Senior Vice President, effective January 2, 2013.
- Role Transition: Patrick Keran, President and Chief Operating Officer, ceased serving as the principal financial officer.
- Compensation Adjustment: Ms. Roberts' annual base salary increased to $250,000.
- Equity Grant: Ms. Roberts received an option award for 75,750 shares at an exercise price of $0.59 per share.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or general risk factors. Specific contingencies related to the equity award include:
- Vesting Schedule: Options vest in 48 monthly installments over 48 months, contingent on continued service.
- Change in Control: Full acceleration of vesting occurs if the successor company does not assume the option, or if Ms. Roberts is terminated without "cause" or for "good reason" within 24 months of a change in control.
- Severance: Ms. Roberts is assigned a nine-month benefit period under the Company's Change in Control Severance Plan.
Investor Verification Checklist
- Verify the correct registrant name (ADVENTRX Pharmaceuticals, Inc.) versus the metadata reference (Savara Inc).
- Confirm the vesting schedule and exercise price ($0.59) of the 75,750 stock options granted to the new CFO.
- Review the December 7, 2012 Form 8-K for details on the Change in Control Severance Plan referenced in this filing.
- Assess the impact of the CFO transition on the company's financial reporting and Sarbanes-Oxley compliance, given Ms. Roberts' prior experience in these areas.